
via Johns Hopkins University School of Medicine
Johns Hopkins Medicine researchers have developed a color-coded test that quickly signals whether newly developed nanoparticles — ultra small compartments designed to ferry medicines, vaccines and other therapies — deliver their cargo into target cells.
Historically, nanoparticles have a very low delivery rate to the cytosol, the inside compartment of cells, releasing only about 1%–2% of their contents. The new testing tool, engineered specifically to test nanoparticles, could advance the search for next-generation biological medicines. The technology builds upon nanoparticles currently used against cancer and eye disease, and in vaccines for viruses including SARS-CoV-2, the virus that causes COVID-19.
The researchers report details of the tool, tested in mouse cells grown in the laboratory and in living mice, in the Jan. 5 issue of Science Advances.
“Many of the current assessment tools for nanoparticles only test whether a nanoparticle reaches a cell, not if the therapy can successfully escape the degradative environment of the endosome to reach inside the cytosol of the cell, which is where the medicine needs to be located for performance,” says Jordan Green, Ph.D., professor of biomedical engineering at the Johns Hopkins University School of Medicine. The new tool was created to track location and nanoparticle release, he said.
Previous research has estimated that only about 1%–2% of nanoparticles “eaten” by cells are able to escape the cellular compartments that trap them to avoid being digested or “spit back out.” In addition to the properties of its cargo, a nanoparticle’s chemical properties determine whether it is accepted by a cell and able to evade its cellular defenses.
To surmount such obstacles to final delivery, Green and his team designed a screening tool that assesses hundreds of nanoparticle formulations on their ability to not just reach a cell, but also how efficiently the nanoparticle can escape with its cargo to reach a cell’s interior.
The test uses mouse cells grown in the laboratory that are genetically engineered to carry a florescent marker called Gal8-mRuby, which shines orange-red when a cellular envelope that engulfs a nanoparticle opens, releasing its cargo into the cell.
Images of the process are then analyzed by a computer program that quickly tracks the nanoparticle location using red fluorescent light and quantifies how effective the nanoparticles are at being released into the cell by assessing the amount of orange-red fluorescent light. , with detailed information about the uptake of the nanoparticles and the delivery of their cargo.
In experiments in mice, Green and his team administered biodegradable nanoparticles carrying mRNA that encoded a gene called luciferase, which makes cells glow. The researchers then tracked whether the mouse cells accepted the gene and began expressing it — lighting up target cells like a lightning bug.
Green’s team found that the top-performing nanoparticles in the cellular tests had a high positive correlation to nanoparticle gene delivery performance in living mice, showing the nanoparticle assay is a good predictor of successful cargo delivery.
In further mouse studies, the researchers discovered that different chemical group combinations in the polymer-based nanoparticles led the nanoparticles to target different tissue types. By analyzing how the particles behaved in the mouse’s body, the researchers found that polymer chemical properties could direct the nanoparticle gene therapy to specific target cells, such as endothelial cells in the lungs or B cells in the spleen.
“By fine-tuning small chemical changes, we can steer a nanoparticle to specific tissues and even specific cells,” said Green. “This would allow us to develop more precisely delivered therapies, which could improve both efficacy and safety.”
Nanoparticle delivery of biological drugs is a growing field, particularly for gene therapies and vaccines.
Original Article: NEW COLOR-CODED TEST QUICKLY REVEALS IF MEDICAL NANOPARTICLES DELIVER THEIR PAYLOAD
More from: Johns Hopkins University School of Medicine
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Medical nanoparticles
- Do Liposomes Make Food Supplements More Effective? A Chemistry Expert Explains Common Myths About These Products
There has been an explosion in nutritional supplements that promise a superior product because they contain nanoparticles called liposomes . But th ...
- 3D-printed plasmonic plastic enables large-scale optical sensor production
In a multi-year project, researchers at Chalmers University of Technology in Sweden have developed plasmonic plastic—a type of composite material with unique optical properties that can be 3D-printed.
- Do liposomes make food supplements more effective? An expert explains common myths about these products
There has been an explosion in nutritional supplements that promise a superior product because they contain nanoparticles called liposomes. But there's a lot of misleading information and outright ...
- Metal & Metal Oxide Nanoparticles Market Set to Reach US$ 89,894.6 Million by 2032 with an Impressive 11.6% CAGR
The global Metal & Metal Oxide Nanoparticles Market is anticipated to register remarkable growth over the projection period ranging from 2022 to 2032. The global market is expected to reach a ...
- New Theory Explains How Nanoparticles Enter and Exit the Tumors
Nanoparticles in the tumor move toward the lymphatic vessel ... Associate Research Director at the Princess Margaret Cancer Center and Professor of Medical Biophysics in U of T’s Temerty Faculty of ...
Go deeper with Google Headlines on:
Medical nanoparticles
[google_news title=”” keyword=”medical nanoparticles” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Nanoparticle drug delivery
- Ocular Drug Delivery Technology Market Surging At A 8.4% CAGR To Cross US$ 39 Billion By 2032 X Herald
The ocular drug delivery technology market is anticipated to grow from US$ 16.4 billion in FY 2021 to US$ 17.74 billion in FY 2022. The industry saw ...
- Sartorius, SPARTA Biodiscovery Partner on Nanoparticle Analysis Platform
SPARTA technology aims to accelerate development, manufacture and QC of nanoparticles used for gene therapies, vaccines, and cancer drugs.
- Sartorius Forms Partnership with SPARTA Biodiscovery on Novel Nanoparticle Analysis Platform
SPARTA technology to accelerate the development, manufacture and quality control of nanoparticles used for gene therapies, vaccines, and cancer drugsSartorius enters into minority ...
- Defence's Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA Vaccines
Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug ...
- Nanoparticles made from plant viruses could be farmers' new ally in pest control
The work is detailed in a paper published in Nano Letters. Steinmetz's team drew inspiration from nanomedicine, where nanoparticles are being created for targeted drug delivery, and adapted this ...
Go deeper with Google Headlines on:
Nanoparticle drug delivery
[google_news title=”” keyword=”nanoparticle drug delivery” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]